|
|
|
|
|
Sponsored by: |
Fox Chase Cancer Center |
Information provided by: | Fox Chase Cancer Center |
ClinicalTrials.gov Identifier: | NCT00394147 |
The purpose of this study is to look at how well the combination of two chemotherapy drugs, pemetrexed (Alimta) and gemcitabine (Gemzar) work to treat your cancer.
Condition | Intervention | Phase |
Head and Neck Cancer |
Drug: pemetrexed |
Phase II |
MedlinePlus related topics: | Cancer Head and Neck Cancer |
ChemIDplus related topics: | Gemcitabine hydrochloride Gemcitabine Pemetrexed disodium Pemetrexed |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Factorial Assignment, Safety/Efficacy Study |
Official Title: | Phase II Trial of Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer (SCCHN) |
Estimated Enrollment: | 32 |
Study Start Date: | October 2006 |
Estimated Study Completion Date: | October 2008 |
This research study is being done because we have not yet been able to find the best treatment for recurrent or advanced head and neck cancer (SCCHN). Pemetrexed and gemcitabine have helped fight against SCCHN when each was given by itself. This study is different from others because it tests these two drugs together, which has not been tried before in patients with SCCHN. We will see how well these drugs can work to help to control or shrink your cancer.
We also want to find out what effects (good and bad) gemcitabine and pemetrexed have on you and your head and neck cancer. We do not know if these drugs will help you. Your cancer might get better or it might get worse. It might not have any effect on your condition. We can use what we learn from this research study to help other people with the same cancer.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Corey Langer, MD | 215-728-6900 | cj_langer@fccc.edu |
Contact: Holly Tuttle, MSN | 215-728-2451 | holly.tuttle@fccc.edu |
United States, Pennsylvania | |||||
Fox Chase Cancer Center | Recruiting | ||||
Philadelphia, Pennsylvania, United States, 19111 |
Fox Chase Cancer Center |
Principal Investigator: | Corey Langer, MD | Fox Chase Cancer Center - Medical Oncology |
Study ID Numbers: | FER-HN-003 |
First Received: | October 27, 2006 |
Last Updated: | October 31, 2007 |
ClinicalTrials.gov Identifier: | NCT00394147 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|